The grades of five Biotechnology stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).
Array BioPharma (NASDAQ:ARRY) is progressing from last week’s rating of B (“buy”) as the company improves to an A (“strong buy”) this week. Array BioPharma is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, inflammatory and metabolic diseases. In Portfolio Grader’s specific subcategory of Earnings Revisions, ARRY also gets an A. Shares of ARRY have increased 33% over the past month, better than the 3.9% increase the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of ARRY stock.
This is a strong week for Alnylam Pharmaceuticals (NASDAQ:ALNY). The company’s rating climbs to A from the previous week’s B. Alnylam Pharmaceuticals engages in discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi). Wall Street has pushed the stock higher by 31.5% over the past month. For more information, get Portfolio Grader’s complete analysis of ALNY stock.
DUSA Pharmaceuticals (NASDAQ:DUSA) ups its rating to a B (“buy”) this week after earning a C (“hold”) in the week before. DUSA Pharmaceuticals is a vertically integrated dermatology company that is developing and marketing pharmaceuticals for the treatment of skin conditions such as actinic keratoses and acne. For more information, get Portfolio Grader’s complete analysis of DUSA stock.
Gentium‘s (NASDAQ:GENT) ratings are looking better this week, moving up to a B from last week’s C. Gentium is a biopharmaceutical company focused on the discovery, research, development, and manufacture of drugs for the treatment and prevention of a variety of vascular diseases and conditions related to cancer and cancer treatments. Wall Street seems to agree with the upgrade and has propelled the stock up 8.1% over the past month. For more information, get Portfolio Grader’s complete analysis of GENT stock.
The rating of Discovery Laboratories (NASDAQ:DSCO) moves up this week, rising from a C to a B. Discovery Laboratories is a biotechnology company focused on developing products for the treatment of respiratory disease. For more information, get Portfolio Grader’s complete analysis of DSCO stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.